Found 0 matching trials
Disitamab Vedotin Combined With Ivonescimab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer PHASE1 This is a single-arm, open-label, Phase Ib/II clinical trial designed to ev...
Show More Location
Sun Yat-sen University Cancer Center
Learn More & Join Trial
Bladder-Sparing Treatment With Disitamab Vedotin and Toripalimab With or Without Pelvic Lymph Node Dissection in Bladder Cancer PHASE2 This is a prospective, multicenter, randomized controlled superiority study...
Show More Location
The Second Hospital of Tianjin Medical University
Learn More & Join Trial
Efficacy and Safety of Two Bladder-preserving Treatment Durations With Disitamab Vedotin Plus Toripalimab Combination in Her2-expressing Muscle-invasive Bladder Cancer: A Phase II, Open-Label, Randomized Clinical Trial PHASE2 This study aims to evaluate the efficacy of disitamab vedotin combined with...
Show More Location
Multiple Locations
Learn More & Join Trial
DV Combined With PD-1 and Platinum-based First-line Treatment in Patients With HER2 IHC2+/3+ ESCC PHASE1 This is a single-arm, exploratory clinical study....
Location
Multiple Locations
Learn More & Join Trial
RC48 Plus Tislelizumab, Low-dose Capecitabine and Celecoxib for HER2-positive Metastatic Colorectal Cancer PHASE2 As an established therapeutic target, HER2 is widely used in a variety of t...
Show More Location
The Sixth Affiliated Hospital of Sun Yat-sen University
Learn More & Join Trial
A Clinical Study of the Efficacy and Safety of Disitamab Vedotin in Combination With Radiotherapy for the Adjuvant Treatment of HER2 Overexpressing UTUC Patients With High Risk Factors for Recurrence After Radical Surgery PHASE2 In this study, 60 patients with HER2 overexpression UTUC with high-risk rec...
Show More Location
Peking University First Hospital
Learn More & Join Trial
RC-48 Combined With GLS-010 in HER2-overexpressed Patients With Previously Treated Unresectable Biliary Tract Cancer NA This is a multicenter, single-arm, open-labal, phase II clinical study with...
Show More Location
Jiangsu Province Hospital
Learn More & Join Trial
DV Combined With Toripalimab for Renal Preservation in Solitary Kidney or Renal Insufficiency or Bilateral Multiple UTUC PHASE2 Approximately 20 participants will be enrolled in the study to evaluate the...
Show More Location
Fudan University Shanghai Cancer Center
Learn More & Join Trial
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 PHASE3 This study will enroll participants with urothelial cancer (UC). UC can inc...
Show More Status
Active Not Recruiting
Location
Banner Gateway Medical Center
Learn More & Join Trial
DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBC PHASE3 The purpose of this study is to learn about the safety and effects of the s...
Show More Location
Fudan University Shanghai Cancer Center
Learn More & Join Trial